DYP688

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Metastatic Uveal MelanomaMetastatic uveal melanomaother GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

Phase 1

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Active, not recruitingNCT05415072

Novartis PharmaceuticalsMetastatic Uveal Melanoma

Start: 2022-07-04End: 2027-10-01Updated: 2026-07-28

As Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas

SuspendedCTIS2023-509451-14-00

Novartis Pharma AGMetastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

Start: 2022-11-01Target: 27Updated: 2025-11-18

Related Papers

An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

Nature Medicine2026-07-13

A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.

Journal of Clinical Oncology2025-05-282 citations

Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma

Molecular Cancer Therapeutics2024-12-092 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations